

QUADRAMED CORP
Form 8-K
December 14, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 10, 2007

QuadraMed Corporation

(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-32283
(Commission File Number)

52-1992861
(I.R.S. Employer
Identification No.)

12110 Sunset Hills Road, Suite 600, Reston, VA 20190

(Address of principal executive office and zip code)

(703) 709-2300

(Registrant's telephone number, including area code)

(Not Applicable)

(Former name or former address, if changed since last report)

Edgar Filing: QUADRAMED CORP - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.	3
SIGNATURES	

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On December 10, 2007, the Board of Directors (the Board) of QuadraMed Corporation (the Company), based on the recommendation of the Company's Compensation Committee of the Board, approved a grant of options to purchase a total of 250,000 shares of common stock to Keith B. Hagen, the Company's President and Chief Executive Officer, as bonus compensation for his performance in 2007. Each of the stock options granted to Mr. Hagen has an exercise price of \$1.99 per share (the closing price of the Company's common stock on December 10, 2007). The options expire ten years from the date of grant, and vest as follows: (i) 25% of the options on the first anniversary of the grant date and (ii) the remaining 75% of the options in a series of thirty-six (36) equal monthly installments upon Mr. Hagen's completion of each month of service with the Company after the first anniversary of the grant date. These 250,000 stock options are bonus compensation in addition to the bonus compensation for which Mr. Hagen is eligible under his Employment Agreement, which was filed as Exhibit 99.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 29, 2005.

In addition, on December 10, 2007, the Board, upon the recommendation of the Compensation Committee, approved increases in annual base salary, effective January 1, 2007, for Mr. Hagen from \$440,750 to \$484,750, for David L. Piazza, the Company's Chief Financial Officer and Executive Vice President, from \$250,000 to \$300,000, and for Steven V. Russell, the Company's Senior Vice President of Corporate Development, from \$235,000 to \$275,000.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 14, 2007

QuadraMed Corporation

/s/ David L. Piazza
David L. Piazza,

Executive Vice President and Chief Financial Officer